Medtronic (NYSE:MDT) Issues Q2 2027 Earnings Guidance

Medtronic (NYSE:MDT) issued an update on its second quarter 2027 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 1.320-1.340 for the period, compared to the consensus estimate of 1.350. The company issued revenue guidance of -. Medtronic also updated its FY 2027 guidance to 5.940-6.000 EPS.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Mizuho reduced their price target on Medtronic from $120.00 to $100.00 and set an “outperform” rating for the company in a research report on Wednesday, June 3rd. Truist Financial lowered their price target on Medtronic from $95.00 to $86.00 and set a “hold” rating on the stock in a report on Thursday, June 4th. Royal Bank Of Canada restated an “outperform” rating and set a $118.00 price objective on shares of Medtronic in a research note on Thursday, June 4th. Wells Fargo & Company reduced their price objective on shares of Medtronic from $114.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, June 4th. Finally, TD Cowen increased their target price on shares of Medtronic from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Friday. Eighteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Medtronic currently has an average rating of “Moderate Buy” and a consensus target price of $99.79.

Medtronic Price Performance

NYSE MDT traded up $0.90 on Tuesday, reaching $91.55. The company’s stock had a trading volume of 4,504,376 shares, compared to its average volume of 8,802,534. Medtronic has a twelve month low of $73.31 and a twelve month high of $106.33. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. The firm’s 50 day moving average is $85.81 and its two-hundred day moving average is $85.48. The stock has a market cap of $117.18 billion, a PE ratio of 24.52, a PEG ratio of 2.45 and a beta of 0.55.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The business had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. During the same period in the previous year, the firm earned $1.26 EPS. The business’s revenue for the quarter was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, sell-side analysts predict that Medtronic will post 5.94 EPS for the current year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. Medtronic’s dividend payout ratio is currently 77.21%.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the sale, the executive vice president owned 37,227 shares in the company, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.27% of the company’s stock.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic raised its fiscal 2027 guidance, increasing organic revenue growth expectations to 7.25%–7.75% and diluted non-GAAP EPS guidance to $5.94–$6.00. The company cited broad-based demand and strength in newer growth platforms. Medtronic boosts fiscal 2027 forecasts on heart device demand
• Positive Sentiment: Fiscal first-quarter revenue rose 13.7% to $9.756 billion, exceeding the $9.55 billion analyst consensus. Adjusted EPS was $1.45 versus expectations of $1.39, while GAAP net income was $1.47 billion and GAAP EPS was $1.14. Medtronic Q1 Revenue Rises 13.7% to $9.756 Billion, Raises FY27 Guidance
• Positive Sentiment: All major businesses posted strong growth: Cardiovascular revenue increased 19.5%, Neuroscience 10.3%, Medical Surgical 10.0%, and Diabetes 16.9% on a reported basis. Cardiovascular demand was especially strong in complex procedures. Medtronic Lifts Outlook, Invests Over $700 Million in Heart Tech and Robotics
• Positive Sentiment: Medtronic is investing more than $700 million in heart technology and robotics, including a strategic investment in Pi-Cardia to advance complex transcatheter aortic valve replacement procedures. The spending could strengthen longer-term growth but may increase near-term investment costs. Medtronic Announces Strategic Investment in Pi-Cardia
• Neutral Sentiment: An additional fiscal week contributed approximately $570 million to first-quarter organic revenue, creating a comparison benefit investors will need to consider when assessing the underlying growth rate.
• Negative Sentiment: Recent insider activity was entirely selling, with three reported open-market sales and no purchases over the past six months. Institutional positioning was also mixed, with major investors both adding to and reducing their holdings.

Institutional Investors Weigh In On Medtronic

Hedge funds have recently modified their holdings of the stock. Brighton Jones LLC increased its stake in Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after purchasing an additional 37,265 shares in the last quarter. Sivia Capital Partners LLC lifted its stake in Medtronic by 9.6% during the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock valued at $380,000 after buying an additional 381 shares in the last quarter. Strive Financial Group LLC acquired a new position in shares of Medtronic in the fourth quarter worth about $143,000. Kelleher Financial Advisors acquired a new position in shares of Medtronic in the third quarter worth about $126,000. Finally, Triumph Capital Management increased its position in shares of Medtronic by 25.1% in the fourth quarter. Triumph Capital Management now owns 887 shares of the medical technology company’s stock worth $85,000 after acquiring an additional 178 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).